Bicalutamide placebo

DRUG2 trials

Sponsors

Janssen - Cilag International, Aragon Pharmaceuticals, Inc.

Conditions

High- or very-high riskProstatic Neoplasmslocalized or locally advanced prostate cancer

Phase 3

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Active, not recruitingNCT02531516

Aragon Pharmaceuticals, Inc.Prostatic Neoplasms

Start: 2015-11-19End: 2028-12-29Updated: 2026-03-19

Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy

Active, not recruitingCTIS2023-505246-26-00

Janssen - Cilag InternationalHigh- or very-high risk, localized or locally advanced prostate cancer

Start: 2016-01-27Target: 635Updated: 2025-12-16

Related Papers

Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).

Journal of Clinical Oncology2022-06-019 citations

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial

BMC Cancer2018-04-0219 citations

Phase-III-Studie beim lokalen oder lokal fortgeschrittenen Prostatakarzinom: Randomisierte, doppelblinde, Placebo-kontrollierte Phase 3 Studie zu Apalutamide in Patienten mit lokalem Hoch-Risiko-Prostatakarzinom oder lokal fortgeschrittenem Prostatakarzinom, die eine primäre Radiotherapie erhalten (ATLAS) – Studie AP 90/15 der AUO

Aktuelle Urologie2017-12-01

ATLAS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy.

Journal of Clinical Oncology2016-05-2023 citations